Merck & Company (MRK) : Traders are bullish on Merck & Company (MRK) as it has outperformed the S&P 500 by a wide margin of 7.31% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.05%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.02% in the last 1 week, and is up 7.72% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Merck & Co., Inc. is up 15.91% in the last 3-month period. Year-to-Date the stock performance stands at 21.99%. The stock has recorded a 20-day Moving Average of 4.21% and the 50-Day Moving Average is 7.55%.
Merck & Company (NYSE:MRK): The stock opened at $63.18 on Friday but the bulls could not build on the opening and the stock topped out at $63.44 for the day. The stock traded down to $62.87 during the day, due to lack of any buying support eventually closed down at $63.36 with a loss of -0.42% for the day. The stock had closed at $63.63 on the previous day. The total traded volume was 8,480,039 shares.
Also, In the latest statement by the brokerage house, UBS maintains its outlook on Merck & Company (NYSE:MRK). The current rating of the shares is Buy, according to the research report released by the firm. The brokerage firm raises the price target from $62 per share to $70 per share. The rating by the firm was issued on August 19, 2016.
Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.